2018 International Congress » Parkinson's Disease: Pathophysiology

1:15pm-2:45pm

A metabolomic signature of treated and drug-naïve patients with Parkinson disease: A pilot study

J. Troisi, A. Landolfi, C. Vitale, K. Longo, A. Cozzolino, M. Squillante, M.C. Savanelli, P. Barone, M. AmbonI (Salerno, Italy)

1:15pm-2:45pm

A patient with myotonic dystrophy type 1 and parkinsonism

J. Choi, J. Lee, H. Kim, B. Jeon (Seoul, Republic of Korea)

1:15pm-2:45pm

A post-mortem and in vivo study of neuroinflammation and Toll like-receptors in Parkinson’s disease

A. Kouli, W.L. Kuan, K. Scott, X. He, R. Barker, C. Williams-Gray (Cambridge, United Kingdom)

1:15pm-2:45pm

Activation of chaperone-mediated autophagy reduces oligomeric alpha-synuclein accumulation in LRRK2(R1441G) knockin mouse model of Parkinson’s disease (PD)

P.W.L. Ho, C.S.C. Lam, M.C.T. Leung, S.Y.Y. Pang, H.F. Liu, L. Li, M.H.W. Kung, D. Ramsden, SL. Ho (Hong Kong)

1:15pm-2:45pm

Alpha-synuclein oligomer and rotenone treatments injury the dopaminergic neuron via inhibiting the expression of gene SEMA6D

X. Yingyu (Guangzhou, China)

1:15pm-2:45pm

Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease

Y. Xiaodong, Q. Yiwei, X. Shaoqing, C. Shengdi, X. Qin (Shanghai, China)

1:15pm-2:45pm

Antibodies to alpha-Synuclein in Parkinson disease

D. Labunskiy (Santa Rosa, CA, USA)

1:15pm-2:45pm

Apathy in Parkinson’s disease is associated with abnormal alpha oscillatory behaviour during incentivized movement

M. Zhu, S. Garg, A. HajiHosseini, S. Appel-Cresswell, M. McKeown (Vancouver, BC, Canada)

1:15pm-2:45pm

Assessment of clinical peculiarities of violations of vertical vision in patients with Parkinson’s disease

M. Salokhiddinov, D. Akramova (Tashkent city, Uzbekistan)

1:15pm-2:45pm

Association between serum Vitamin D levels and Parkinson’s disease: A systematic review and meta-analysis

XY. Luo, R. Ou, HF. Shang (Chengdu, China)

1:15pm-2:45pm

Automated immunohistochemical detection of pathological alpha-synuclein in human tissue biopsy

TS. Tsao, A. Racolta, H. Zhang, M. Robida, J. Pugh, T. Beach, T. Kremer, C. Czech, K. Taylor, W. Zago, L. Pestic-Dragovich, L. Tang, S. Dziadek (Tucson, AZ, USA)

1:15pm-2:45pm

B lymphocytes may be protective in early Parkinson’s disease and in an animal model of dopaminergic cell death

K. Scott, C. Williams-Gray, R. Wijeyekoon, S. Hayat, K. Hall, P. Tyers, R. Mathews, R. Barker, M. Clatworthy (Cambridge, United Kingdom)

1:15pm-2:45pm

Bidirectional gut-to-brain and brain-to-gut propagation of α-synuclein pathology in non-human primates

ML. Arotçarena, S. Dovero, A. Prigent, M. Bourdenx, P. Aubert, I. Trigo, G. Porras, ML. Thiolat, M. Tasselli, C. Estrada, A. Recasens, J. Blesa, M. Herrero, N. Carillo, M. Vila, J. Obeso, P. Derkinderen, B. Dehay, E. Bezard (Bordeaux, France)

1:15pm-2:45pm

Bmal1 deficiency aggravates MPTP-induced dopaminergic cell death through promoting neuroinflammation

C. Gu, W. Liu, X. Gu, F. Wang, Y. Yang, C. Liu (Su Zhou, China)

1:15pm-2:45pm

Bone health and laboratorial correlations of Vitamin D in Parkinson’s disease

L. Leandro, C. Moreira, H. Teive (Curitiba, Brazil)

1:15pm-2:45pm

Carrier Mediated Delivery System Bearing Dopamine for Effective Management of Parkinsonism

M. Bhargava, S. Bhargava (Kanpur, India)

1:15pm-2:45pm

Catecholamines interrelation in plasma of early diagnosed treatment-naive patients with Parkinson disease

D. Khasanova, Z. Zalyalova, M. Ugrumov (Kazan, Russian Federation)

1:15pm-2:45pm

Cell and animal models lacking RAB39B show biochemical and behavioural phenotypes that model aspects of Parkinson’s disease

Y. Gao, G. Wilson, S. Stephenson, K. Bozaoglu, M. Dottori, P. Thomas, P. Lockhart (Melbourne, Australia)

1:15pm-2:45pm

Characterization of the preclinical model parkinQ311X

A. Ciammola, M. Regoni, D. Mercatelli, L. Croci, G. Serratto, S. Fasano, L. Murru, S. Novello, M. Pingue, V. Silani, G. Consalez, F. Valtorta, M. Passafaro, M. Morari, J. Sassone (Milan, Italy)

1:15pm-2:45pm

Classification of Dopaminergic-State and Motor Activity by Theta, Beta and Gamma Activity in Parkinson’s Disease

I. Weber, C. Oehrn, N. Apetz, T. Dembek, F. Jung, E. Florin, L. Timmermann (Marburg, Germany)

1:15pm-2:45pm

Clinical correlates of stuttering in advanced Parkinson’s disease

T. Tsuboi, H. Watanabe, Y. Tanaka, R. Ohdake, M. Hattori, K. Kawabata, K. Hara, D. Nakatsubo, S. Maesawa, Y. Kajita, T. Wakabayashi, M. Katsuno, G. Sobue (Nagoya, Japan)

1:15pm-2:45pm

Cortical correlates of dual-task turning with and without freezing of gait

M. Mancini, S. Stuart (Portland, OR, USA)

1:15pm-2:45pm

Decreased amyloid-beta in patients with Idiopathic Parkinson’s Disease and white matter hyperintensities

I. Markaki, S. Klironomos, P. Svenningsson (Stockholm, Sweden)

1:15pm-2:45pm

Deletion of GBA2 in neuronopathic Gaucher’s disease medaka can’t rescue the phenotype

E. Nakanishi, N. Uemura, H. Akiyama, M. Kinoshita, H. Yamakado, S. Takeda, Y. Hirabayashi, R. Takahashi (Kyoto, Japan)

1:15pm-2:45pm

Determination of falling direction in Parkinson’s disease patients using a wearable sensor

Y. Okuma, H. Mitoma (Izunokuni, Japan)

1:15pm-2:45pm

Dietary habits, motor and cognitive impairment in Parkinson’s Disease

A. Pilotto, MC. Rizzetti, m. Oppini, C. passeri, A. Alberici, R. Turrone, M. Cosseddu, D. Placidi, M. Turla, b. Borroni, R. Lucchini, A. Padovani (Brescia, Italy)

1:15pm-2:45pm

Direction of Turning in Parkinson’s Disease: More Affected Side or Less Affected Side?

S.M. Cheon, J.W. Kim (Busan, Republic of Korea)

1:15pm-2:45pm

Distinct Blood Leukocytes Expression Profiles of Long Non-coding RNAs and mRNAs in Parkinson’s disease patients

Y. Fan, Z. Xue (Wuhan, China)

1:15pm-2:45pm

Effects of Glial Heme Oxygenase-1 on Neuronal Alpha-Synuclein in the GFAP.HMOX1 Mouse Model of Parkinson’s Disease

M. Cressatti, W. Song, A. Turk, C. Galindez, H. Schipper (Montreal, QC, Canada)

1:15pm-2:45pm

Effects of neural stem cell transplantation on the differentiation of dopaminergic neurons in the substantia nigra and changes to rotational behavior of Parkinson’s disease rats

J.J. Xiao, X.P. Wang (Shanghai, China)

1:15pm-2:45pm

Enhancing protein palmitoylation is protective in alpha-synuclein dependent cytotoxicity

G. Ho, T. Imberdis, S. Nuber, U. Dettmer, D. Selkoe (Boston, MA, USA)

1:15pm-2:45pm

Examination of paravertebral muscular force in camptocormia

R. Wolke, N. Margraf, J. Kuhtz-Buschbeck, G. Deuschl (Kiel, Germany)

1:15pm-2:45pm

Experimental rotenone model

X. Djakhangir, A. Ziyoda (Tashkent, Uzbekistan)

1:15pm-2:45pm

Freezing of Gait in Parkinson’s Disease: Clinico-biochemical Observations

B. Mondal, R. Banerjee, K. Chatterjee, A. Roy, S. Shubham, P. Basu, S. Choudhury, H. Kumar (Kolkata, India)

1:15pm-2:45pm

Freezing of gait recognition in Parkinson’s disease: A subject independent objective method

V. Rama Raju (Hyderabad, India)

1:15pm-2:45pm

Frontal-subcortical cognitive impairments in Parkinson’s patients with freezing of gait

J. Garcia-Caldentey, MA. Prats-Sedano, E. Estelrich-Peyret, PJ. Garcia-Ruiz (Palma de Mallorca, Spain)

1:15pm-2:45pm

GBA haploinsufficiency accelerated alpha synuclein pathology with altered lipid metabolism in a premotor model of Parkinson’s disease

H. Yamakado, M. Ikuno, H. Akiyama, L. Parajuli, K. Taguchi, J. Hara, N. Uemura, Y. Hatanaka, K. Higaki, M. Tanaka, M. Koike, Y. Hirabayashi, R. Takahashi (Kyoto, Japan)

1:15pm-2:45pm

Identification of putative serum biomarkers for parkin-related Parkinson’s disease by metabolome analysis

T. Ogawa, T. Hatano, A. Okuzumi, S. Ueno, A. Mori, Y. Oji, M. Fujimaki, T. Koinuma, S. Saiki, N. Hattori (Tokyo, Japan)

1:15pm-2:45pm

Influence of dopamine deficiency on interhemispheric crosstalk in Parkinson’s disease

P. Loehrer, F. Nettersheim, I. Weber, F. Jung, L. Timmermann (Marburg, Germany)

1:15pm-2:45pm

Insulin degrading enzyme, a novel key protein against alpha-synuclein oligomers formation?

I. Martinez-Valbuena, R. Valenti-Azcarate, I. Amat-Villegas, I. Marcilla-Garcia, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, MT. Tuñon-Alvarez, MR. Luquin-Piudo (Pamplona, Spain)

1:15pm-2:45pm

Interaction of TDP-43 with IAPP in pancreatic beta cells of patients with sinucleinopathies

R. Valenti-Azcarate, I. Martinez-Valbuena, C. Arean-Cuns, I. Marcilla-García, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, MT. Tuñon-Alvarez, MR. Luquin Piudo (Pamplona, Spain)

1:15pm-2:45pm

Investigating the role of microRNA biogenesis pathway in neuroprotection in primary neuronal culture model of Parkinson’s disease

J. Konovalova, S. Er, S. Soleimanbeigi, P. Chmielarz, A. Domanskyi (Helsinki, Finland)

1:15pm-2:45pm

Levodopa-induced dyskinesia in Parkinson’s disease: Sleep matters

N. Amato, M. Manconi, J.C. Möller, S. Sarasso, P. Stanzione, C. Städler, A. Kaelin-Lang, S. Galati (Lugano, Switzerland)

1:15pm-2:45pm

Low body weight is associated with poor functional status in Parkinson’s disease (PD)

HF. Chan, N. Cheung, D. Chau, CW. Woo, B. Chee, A. Leung, S. Or, WC. Fong (Hong Kong)

1:15pm-2:45pm

Microbiota DNA in the blood of patients with Parkinson’s disease

S.Q. Xu, Y.W. Qian, X.D. Yang, S.D. Chen, Q. Xiao (Shanghai, China)

1:15pm-2:45pm

Microglial activation, white matter and hippocampal damage correlate with cognitive impairment in chronic cerebral hypoperfused and MPTP-lesioned mice

Y. Gao, H. Tang, K. Nie, R. Zhu, L. Gao, S. Feng, L. Wang, J. Zhao, Z. Huang, Y. Zhang, L. Wang (Guangzhou, China)

1:15pm-2:45pm

Modulation of CaMKIIa-NR2B interaction in levodopa-induced dyskinesia in 6-OHDA- lesioned Parkinson’s rats

XS. Wang, WW. Wang, CL. Xie (Wenzhou, China)

1:15pm-2:45pm

Molecular Genetics and Functional Studies of LRRK2 Gene Variations in Parkinson’s Disease

M-L. Chen, R-M. Wu (Taipei, Taiwan)

1:15pm-2:45pm

Motivational effects on action selection and memory

S. Hirschbichler, J. Ibáñez, L. Rocchi, R. Greenwood, J. Rothwell, S. Manohar (London, United Kingdom)

1:15pm-2:45pm

Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Cerebrospinal Fluid C-Reactive Protein

H. Sanjari Moghaddam, M.H. Aarabi (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm

Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)

L. Chahine, T. Beach, C. Coffey, C. Caspell-Garcia, C. Alder, G. Serrano, S. Mosovsky, T. Foroud, C. Linder, H. Riss, D. Ecklund, J. Seibyl, A. Mallya, V. Arnedo, L. Riley, K. Dave, D. Jennings, B. Mollenhauer (Pittsburgh, PA, USA)

1:15pm-2:45pm

Nanoscale imaging reveals disorganization of the brain extracellular space in Lewy body-injected mice

F. Soria, N. Danne, C. Paviolo, E. Doudnikoff, B. Dehay, L. Groc, L. Cognet, E. Bezard (Bordeaux, France)

1:15pm-2:45pm

Natural occurring antibodies reduce aggregation of α-synuclein

A. Braczynski, E. Agerschou, Y. Kronimus, W. Hoyer, R. Dodel, B. Falkenburger, J. Schulz, J. Bach (Aachen, Germany)

1:15pm-2:45pm

Neurophysiological correlates of bradykinesia in Parkinson’s disease

M. Bologna, A. Guerra, G. Paparella, L. Giordo, D. Alunni Fegatelli, AR. Vestri, J. Rothwell, A. Berardelli (Rome, Italy)

1:15pm-2:45pm

Neuroprotection effects of probiotics strains on a chronic MPTP-induced mouse model of Parkinson’s disease

Y. Qian, X. Yang, S. Xu, Q. Xiao (Shanghai, China)

1:15pm-2:45pm

Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and Parkinson’s Disease: Preliminary report

B. Lisewska, P. Lisewski, P. Szarwas, N. Piekuś-Słomka, D. Rość (Bydgoszcz, Poland)

1:15pm-2:45pm

New evidence for thalamic dysfunction in Parkinsonian rats

L. Grandi, G. Di Giovanni, E. Fedele, G. Orban, A. Salvadè, W. Song, A. Stefani, A. Kaelin-Lang, S. Galati (Taverne, Switzerland)

1:15pm-2:45pm

No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors

F. Hopfner, S. Müller, D. Steppat, J. Miller, N. Schmidt, K.P. Wandinger, F. Leypoldt, D. Berg, A. Franke, W. Lieb, L. Tittmann, M. Balzer-Geldsetzer, S. Baudrexel, R. Dodel, R. Hilker-Roggendorf, E. Kalbe, J. Kassubek, T. Klockgether, I. Liepelt-Scarfone, B. Mollenhauer, P. Neuser, K. Reetz, O. Riedel, C. Schulte, J. Schulz, A. Spottke, A. Storch, C. Trenkwalder, G. Deuschl, G. Kuhlenbäumer (Kiel, Germany)

1:15pm-2:45pm

No MPTP-induced behavioral deficits or Striatal field potential alterations in crossbreds of MPTP-susceptible and MPTP-resistant mice strains

P. Alladi, D. Vidyadhara, S. Arun, B. Kutty (Bengaluru, India)

1:15pm-2:45pm

Partial depletion of peripheral M1 macrophages ameliorates the neuroinflammation and dopaminergic neuronal death in the brain of a MPTP-induced mouse model of PD

A. Yan, Y. Zhang, J. Lin, L. Song, X. Wang, Z. Liu (Shanghai, China)

1:15pm-2:45pm

Peripheral Inflammatory Mediators in Parkinson’s Disease – A Potential Biomarker

K. Chatterjee, A. Roy, R. Banerjee, S. Halder, S. Choudhury, P. Basu, S. Shubham, H. Kumar (Kolkata, India)

1:15pm-2:45pm

Pharmacological modulation of lysosomal glucocerebrosidase activity in the Thy1-aSYN mouse model of Parkinson’s disease

K. Belarbi, E. Cuvelier, H. Carrie, M.A. Bonte, W. Sibran, C. Leghay, J. Von Gerichten, V. Nordström, R. Sandhoff, T. Comptdaer, N. Jouy, E. Mutez, A. Destee, C. Pincon, B. Gressier, M.C. Chartier-Harlin (Lille, France)

1:15pm-2:45pm

Predictors of freezing of gait in newly diagnosed Parkinson’s disease: Clinical, dopamine transporter imaging and CSF markers in the PPMI cohort

R. Kim, J. Lee, H.J. Kim, A. Kim, B. Jeon, U.J. Kang, S. Fahn (Seoul, Republic of Korea)

1:15pm-2:45pm

Prefrontal cortical stimulation to treat anxiety and depression in Parkinson’s disease

C. de Hemptinne, W. Chen, C. Racine, A. Seritan, A. Miller, J. Mergenthaler, S. Rajagopalan, J. Ostrem, M. San Luciano, P. Starr (San Francisco, CA, USA)

1:15pm-2:45pm

Presence of Lewy dots in the brain of patients with Creutzfeldt-Jakob disease

R. Valenti-Azcarate, I. Martinez-Valbuena, M. Tuñon-Alvarez, I. Marcilla-Garcia, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, E. Erro-Aguirre, M. Luquin-Piudo (Pamplona, Spain)

1:15pm-2:45pm

Prevalence and risk factor of peak-dose dyskinesia in Thai patients with Parkinson’s disease

S. Klanbut, C. Luangsinsiri, N. Piyaparneekul, C. Khongbut, K. Methawasin (Nakhon Nayok, Thailand)

1:15pm-2:45pm

Profiles of microRNA in cerebrospinal fluid could be potential biomarkers for identifying motor subtype of Parkinson’s disease

W. Jang (Gangneung, Republic of Korea)

1:15pm-2:45pm

Properties of oscillatory neuronal activity in the basal ganglia and thalamus in patients with Parkinson’s disease

P. Zhuang, M. Hallett, G. Du, Y. Zhang, Y. Li (Beijing, China)

1:15pm-2:45pm

Protective effects of Mucuna pruriens seed on rat brain: A therapeutic potential drug for Parkinson’s disease

S. Rajput, S. Sinha (New Delhi, India)

1:15pm-2:45pm

PrP as a receptor of alpha-synuclein in the pancreas of patients with synucleinopathies

I. Martinez-Valbuena (Pamplona, Spain)

1:15pm-2:45pm

Pupil evaluation as the test for the clinical manifestations of Parkinson’s disease

T. Araga, M. Shiraishi, K. Shinohara, Y. Hasegawa (Kawasaki, Japan)

1:15pm-2:45pm

Quantitative Keyboard Tapping Measurement Correlates with Electrophysiological Changes in STN LFPs of PD Patients Treated with L-dopa Better Than UPDRS Subscores

M. Ozturk, A. Abosch, D. Francis, J. Wu, N. Ince (Houston, TX, USA)

1:15pm-2:45pm

Red cell distribution with levels in Parkinson’s disease patients

G. Ozgen Kenangil, B.C. Ari, F. Altuntas Kaya, M. Demir, F. Mayda Domac (Istanbul, Turkey)

1:15pm-2:45pm

Reduced vesicular storage of catacholamines enhance MPTP-induced death of dopaminergic neurons in locus coeruleus and olfactory bulb

K. Ma, J. Huang, L. Liu, X. Fang, Y. Xia, F. Wan, S. Yin, L. Kou, N. Xiong, T. Wang (Wuhan, China)

1:15pm-2:45pm

Relationship of Vitamin D deficiency with Parkinson’s disease risk

M. Sanoeva, N. Mansurova (Bukhara, Uzbekistan)

1:15pm-2:45pm

Risk estimation in the years preceding diagnosis of Parkinson’s disease in the PREDICT-PD cohort

S. Auger, D. Rack, J. Bestwick, G. Giovannoni, A. Lees, A. Schrag, A. Noyce (London, United Kingdom)

1:15pm-2:45pm

Role of microglia in the transmission of α-syn-containing exosomes

Y. Xia, G. Zhang, J. Huang, N. Xiong, K. Ma, X. Guo, F. Wan, L. Kou, S. Yin, T. Wang (Wuhan, China)

1:15pm-2:45pm

Saccades in Parkinson’s disease: Hypometric, slow, or maladaptive?

L. Neilson, F. Ghasia, A. Shaikh (Cleveland, OH, USA)

1:15pm-2:45pm

Salivary Alpha-Synuclein a new tool for the diagnosis of Parkinson’s disease?

C. Aerts, C. Hirtz, V. Gonzalez, L. Collombier, M. De Verdal, C. Geny, M. Charif, E. Moulis, P. Fabbro-Peray, D. Deville Periere, P. Lapeyrie, G. Castelnovo, S. Lehmann (Nimes, France)

1:15pm-2:45pm

Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy

G. Vivacqua, A. Fabbrini, R. Mancinelli, D. Belvisi, G. Fabbrini, A. Suppa, A. Berardelli (Cambridge, United Kingdom)

1:15pm-2:45pm

Serum glutamate is associated with the motor subtype of Parkinson’s disease

A. Latypova, I. Mironova, O. Izhboldina, I. Zhukova, N. Zhukova, E. Kolupaeva (Tomsk, Russian Federation)

1:15pm-2:45pm

Serum Leptin levels in Iranian patients with Parkinson’s disease

M. Salari, M. Etemadifar, M. Barzegar (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm

Soluble TREM2 and Central and Peripheral Inflammatory Biomarkers in Parkinson’s Disease

L. Bekris, M. Khrestian, Y. Shao, H. Fernandez, J. Leverenz (Cleveland, OH, USA)

1:15pm-2:45pm

Spatiotemporal patterns of direct and indirect pathway striatal projection neurons in mouse model of Parkinson’s disease and dyskinesia

C. Alcacer, M. Mendonca, A. Klaus, MA. Cenci, R. Costa (Lisbon, Portugal)

1:15pm-2:45pm

Speech intelligibility and comprehensibility in Slovak patients with Parkinson’s disease

A. Kušnírová, Ľ. Mičianová, Z. Košutzká, I. Straka, M. Egryová, P. Valkovič, Z. Cséfalvay (Bratislava, Slovakia)

1:15pm-2:45pm

Status of riding bicycle and reasons for cessation of cycling in patients with Parkinson disease: A Japanese single center cross-sectional survey

K. Takahashi, K. Ota, K. Seo, H. Kawasaki, K. Ikeda, T. Furuya, A. Miyake, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, N. Tamura, N. Araki, T. Yamamoto (Saitama-ken, Japan)

1:15pm-2:45pm

STN DBS – A study of frequency of gait (fog) in Parkinson’s disease

V. Rama Raju, R. Borgohain (Hyderabad, India)

1:15pm-2:45pm

Substantia nigra hyperechogenicity is similarly enlarged in Gaucher and in GBA mutation carriers

D. Arkadir, A. Zimran (Jerusalem, Israel)

1:15pm-2:45pm

T lymphocytes in Parkinson’s disease pathogenesis and therapy: A systematic review

J. Baird, J. Quinn (Portland, OR, USA)

1:15pm-2:45pm

Tau and α-synuclein autoantibodies as potential biomarkers for Parkinson’s and Alzheimer’s diseases

A. Shalash, M. Salama, M. Makar, T. Roushdy, M. El-Balkimy (Cairo, Egypt)

1:15pm-2:45pm

Tetrahydroisoquinoline Molecule Identified in Traditional Ayurveda Medicine Modulates Inflammation in MPTP Mice

R. Banerjee, R. Paidi, P. Jaisankar, K. Mohanakumar, S. Biswas (Kolkata, India)

1:15pm-2:45pm

The Association between Infections and Parkinson Disease: A Systematic Review and Meta-analysis

M. Morra, S. Ghozy, E. Sakr, M. Elfaituri, M. Khattab, M. Mahmoud, S. Mehyar, M. Alhattab, A. Ahmed Ismail, M. Abdelmongy, M. Fahmy, E. Gharib, A. Hallab, N. Huy (Cairo, Egypt)

1:15pm-2:45pm

The difference in posture reaction against backward perturbation between patients with Parkinson’s disease and healthy controls

K. Kannari, S. Koseki, C. Narita, S. Sugo. (Aomori, Japan)

1:15pm-2:45pm

The increased α-syn expression inhibits exosomal secretion

Y. Ishiguro, T. Tsunemi, A. Yoroizaka, W. Akamatsu, N. Hattori (Tokyo, Japan)

1:15pm-2:45pm

The Prevalence of Tandem Gait Abnormality in Parkinson’s Disease

J. Margolesky, S. Bette, D. Shpiner, T. Rundek, C. Luca, H. Moore, C. Singer (Miami, FL, USA)

1:15pm-2:45pm

Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism

R. Cilia, M. Barichella, M. Severgnini, E. Cassani, C. Bolliri, S. Caronni, V. Ferri, R. Cancello, S. Faierman, G. Pinelli, C. Ceccarani, G. De Bellis, L. Zecca, E. Cereda, C. Consolandi, G. Pezzoli (Milan, Italy)

1:15pm-2:45pm

Unveiling the function of altered gut microbiota composition in Parkinson’s disease

A.H. Tan, C.W. Chong, C.S.J. Teh, I.K.S. Yap, M.F. Loke, J. Bowman, S.L. Song, J.Y. Tan, B.H. Ang, Y.Q. Tan, H.S. Yong, A.E. Lang, S. Mahadeva, S.Y. Lim (Kuala Lumpur, Malaysia)

1:15pm-2:45pm

Validation of protein phosphatases that regulate the LRRK2 phosphorylation cycle

M. Drouyer, M. Emanuele, R. Lefebvre, K. Cailliau-Maggio, A. martoriati, T. Comptdaer, P. Semaille, E. Mutez, W. Sibran, N. Wolkoff, E. Lobbestael, M. Bolliger, V. Baekelandt, J. Nichols, MC. Chartier-Harlin, JM. Taymans (Lille, France)

1:15pm-2:45pm

Variable selection using machine-learning to identify new signatures of patient-derived aggregated α-synuclein-induced neurodegeneration in non-human primates

M. Bourdenx, A. Nioche, S. Dovero, M.L. Arotçarena, S. Camus, G. Porras, M.L. Thiolat, N. Rougier, A. Prigent, P. Aubert, S. Bohic, N. Kruse, B. Mollenhauer, S. Novello, M. Morari, I. Trigo, M. Goillandeau, M. Tasselli, C. Perier, N. Garcia Carrillo, C. Estrada, A. Recasens, J. Blesa, M. Herrero, P. Derkinderen, M. Vila, J. Obeso, B. Dehay, E. Bezard (Bordeaux, France)

1:15pm-2:45pm

Vascular risk factors prevalence differences between Vascular Parkinsonism (VaP) and Parkinson Disease (PD) in a hospital cross-section study

A. Velon, M. Mendes, R. Raimundo, R. Jesus, R. Almendra (Vila Real, Portugal)

1:15pm-2:45pm

α-synuclein aggregation and propagation in marmoset brains deteriorates its motor function

T. Yabumoto, K. Baba, H. Hayakawa, K. Ikenaka, F. Yoshida, T. Uehara, R. Nakatani, H. Tsuda, S. Nagano, H. Hamanaka, Y. Nagai, M. Hirata, H. Mochizuki. (Osaka, Japan)

1:15pm-2:45pm

α-synuclein antibody 5G4 identifies manifest and prodromal Parkinson’s disease in colonic mucosa

M. Skorvanek, E. Gelpi, E. Mechirova, Z. Ladomirjakova, V. Han, N. Lesko, E. Feketeova, J. Ribeiro Ventosa, F. Kudela, K. Kulcsarova, S. Babinska, S. Toth, L. Gombosova, F. Trebuna, M. Lutz, Z. Gdovinova, G. Kovacs (Kosice, Slovakia)